- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Gene that Could Identify Tamoxifen-Resistant Breast Cancer Discovered
The study, published in PNAS, identified a gene whose expression could be used as a prognostic indicator and could direct treatment in breast cancer patients.
Johns Hopkins Kimmel Cancer Center identified a gene, MACROD2,
A study conducted by scientists at the which they found is amplified in a subset of breast cancer patients. Deletion and overexpression studies with the gene, in vitro and in a mouse model, found that MACROD2 promotes resistance to tamoxifen and encourages estrogen receptor-independent growth in a mouse xenograft model.
When they examined 2 well-known databases of breast cancer patients' genetic information, The Cancer Genome Atlas and the Molecular Taxonomy of Breast Cancer International Consortium study, it was discovered that patients who had MACROD2 overexpressed in primary breast cancers at the original breast cancer site had significantly worse survival rates than those who did not.
This could mean that patients overexpressing this gene in the primary tumor, early in the disease, could receive aggressive treatment.
The study was published online in PNAS: http://bit.ly/1rcTJBY
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
